Tag: true north

Voxco acquires Bengaluru-based Actify Data Labs

True North announced the signing of a definitive agreement to sell its entire stake in Actify Data Labs, a greenfield data-driven analytics company, to Voxco, a global omni-channel survey platform.  Headquartered in Bengaluru, Actify Data Labs is an augmented intelligence company that delivers rapid business impact using data science and data engineering capabilities. The company…

M&M to Enhance its Ownership to 100 per cent in Meru

In continuation of its strategic intent to grow its presence in the shared mobility space, Mahindra and Mahindra Ltd. (M&M) today announced that it has entered into definitive agreements with shareholders of Meru Travel Solutions Private Limited (Meru) to buy their respective stakes in Meru. It would acquire 44.14% shares from Private Equity investor, True…

Warburg Pincus plans to invest Rs700 cr in Home First

Warburg Pincus, a US based private equity firm, through it’s affiliate Orange Clove Investments BV has announced that it has entered into an agreement to invest about Rs 700 crore in Home First Finance Company India Ltd on October 2, 2020.  The announcement came in from the leading global private equity firm focused on growth…

True North acquires Glenmark’s gynaecology business

True North, a private equity firm, has agreed to acquire Glenmark Pharmaceuticals Ltd’s gynaecology business in India and Nepal for Rs 115 crore. The acquisition will be done through True North’s portfolio company, Integrace Pvt. Ltd. All formalities related to acquisition will be completed by March. The acquisition is the second such engagement between True…

True North to invest ₹536.25 cr in Biocon Biologics for 2.44% stake

Biocon Ltd, an innovation-led global biopharmaceuticals company, today announced that the Board of its subsidiary Biocon Biologics India Ltd has approved a primary equity investment by True North. As per the terms of the proposed agreement, True North will invest ₹ 536.25 Crore that will eventually translate to a 2.44% minority stake in the biosimilars…